CHILDREN'S HOSPITAL OF EASTERN ONTARIO RESEARCH INSTITUTE INC. (Canada)
Inventeur(s)
Alain, Tommy
Hoang, Huy-Dung
Graber, Tyson
Abrégé
The present invention is directed to nucleic acids, vectors, compositions, kits, and cell lines comprising US11 5' leader sequence (SEQ ID NO: 1 or SEQ ID NO: 4), UL27 5' leader sequence (SEQ ID NO: 7 or SEQ ID NO: 10), or UL19 5' leader sequence (SEQ ID NO: 13 or SEQ ID NO: 16) whereby the leader sequences are capable of enhancing translation of a downstream gene encoding a protein of interest, resulting in increased protein production, expression or synthesis in HSV1 infected cells. The 5' leader increases protein expression by several fold compared to protein expression in the absence of the leader sequence. Methods of increasing protein production, methods of increasing efficiency of existing gene therapies, and methods of treating a medical condition, cellular defect, disease or disorder are also provided.
A61K 35/68 - Protozoaires, p. ex. flagelles, amibes, sporozoaires, plasmodium ou toxoplasma
A61K 48/00 - Préparations médicinales contenant du matériel génétique qui est introduit dans des cellules du corps vivant pour traiter des maladies génétiquesThérapie génique
CHILDREN'S HOSPITAL OF EASTERN ONTARIO RESEARCH INSTITUTE INC. (Canada)
Inventeur(s)
Stojdl, David F.
Abrégé
The present disclosure concerns an oncolytic virus for the treatment of cancer, such as in brain cancer, for example glioblastoma. The oncolytic virus may exhibit reduced levels of neurotoxicity. The oncolytic virus may be an isolated viral particle capable of producing a cDNA polynucleotide that includes a sequence according to SEQ ID NO: 1 when the virus is in a host cell. The oncolytic virus may be an isolated viral particle that includes an RNA polynucleotide that includes a sequence according to SEQ ID NO: 2. The oncolytic virus may be an isolated viral particle having a genome that includes open reading frames that encode: proteins having sequences comprising SEQ ID NOs: 3, 4, 5, 6 and 7; or variants thereof.
CHILDREN'S HOSPITAL OF EASTERN ONTARIO RESEARCH INSTITUTE INC. (Canada)
Inventeur(s)
Stojdl, David F.
Abrégé
The present disclosure provides a Farmington virus formulated to induce an immune response in a mammal against a tumour associated antigen. The Farmington virus may express an antigenic protein that includes an epitope from the tumour associated antigen. The Farmington virus may be formulated in a composition where the virus is separate from an antigenic protein that includes an epitope from the tumour associated antigen. The present disclosure also provides a prime:boost therapy for use in inducing an immune response in a mammal. The boost includes a Farmington virus, or a composition that includes a Farmington virus.
A61K 39/205 - Rabdoviridae, p. ex. virus de la rage
C07K 14/005 - Peptides ayant plus de 20 amino-acidesGastrinesSomatostatinesMélanotropinesLeurs dérivés provenant de virus
C07K 14/47 - Peptides ayant plus de 20 amino-acidesGastrinesSomatostatinesMélanotropinesLeurs dérivés provenant d'animauxPeptides ayant plus de 20 amino-acidesGastrinesSomatostatinesMélanotropinesLeurs dérivés provenant d'humains provenant de vertébrés provenant de mammifères
C12N 7/00 - Virus, p. ex. bactériophagesCompositions les contenantLeur préparation ou purification
4.
METHODS FOR INDUCING AN IMMUNE RESPONSE AGAINST NEOANTIGENS
CHILDREN'S HOSPITAL OF EASTERN ONTARIO RESEARCH INSTITUTE INC. (Canada)
Inventeur(s)
Stojdl, David
Kmiecik, Justyna
Burgess, Michael F.
Abrégé
In one aspect, provided herein is a heterologous boost method for inducing an immune response to at least one neoantigen, the method comprising administering to a subject a first boost and subsequently administering to the subject a second boost, wherein the first boost comprises a first oncolytic virus comprising a genome that expresses, in the subject, a first peptide, or the first boost comprises a first oncolytic virus and a second peptide, wherein the second boost comprises a second oncolytic virus comprising a genome that expresses, in the subject, a third peptide, or the second boost comprises a second oncolytic virus and a fourth peptide, wherein the first peptide, the second peptide, the third peptide, and the fourth peptide are each capable of inducing an immune response to at least one neoantigen, and wherein the second oncolytic virus is immunologically distinct from the first oncolytic virus. The subject may have pre-existing immunity to the at least one neoantigen. The subject may have been administered a priming composition before receiving the first boost, wherein the priming composition is capable of inducing an immune response to the at least one neoantigen.
CHILDREN'S HOSPITAL OF EASTERN ONTARIO RESEARCH INSTITUTE INC. (Canada)
TURNSTONE BIOLOGICS INC. (Canada)
Inventeur(s)
Stojdl, David
Kmiecik, Justyna
Burgess, Michael F.
Abrégé
The present disclosure relates to a sequential boost oncolytic viral immunotherapy and compositions for use in the same. More particularly, the disclosure relates to oncolytic viruses that significantly increase antigen-specific T cell-mediated immune responses when combined in a sequential heterologous boost treatment regimen.
CHILDREN'S HOSPITAL OF EASTERN ONTARIO RESEARCH INSTITUTE INC. (Canada)
Inventeur(s)
Stojdl, David F.
Abrégé
The present disclosure concerns an oncolytic virus for the treatment of cancer, such as in brain cancer, for example glioblastoma. The oncolytic virus may exhibit reduced levels of neurotoxicity. The oncolytic virus may be an isolated viral particle capable of producing a cDNA polynucleotide that includes a sequence according to SEQ ID NO: 1 when the virus is in a host cell. The oncolytic virus may be an isolated viral particle that includes an RNA polynuclotide that includes a sequence according to SEQ ID NO: 2. The oncolytic virus may be an isolated viral particle having a genome that includes open reading frames that encode: proteins having sequences comprising SEQ ID NOs: 3, 4, 5, 6 and 7; or variants thereof.
CHILDREN'S HOSPITAL OF EASTERN ONTARIO RESEARCH INSTITUTE INC. (Canada)
Inventeur(s)
Stojdl, David
Kmiecik, Justyna
Burgess, Michael F.
Abrégé
In one aspect, provided herein is a heterologous boost method for inducing an immune response to at least one neoantigen, the method comprising administering to a subject a first boost and subsequently administering to the subject a second boost, wherein the first boost comprises a first oncolytic virus comprising a genome that expresses, in the subject, a first peptide, or the first boost comprises a first oncolytic virus and a second peptide, wherein the second boost comprises a second oncolytic virus comprising a genome that expresses, in the subject, a third peptide, or the second boost comprises a second oncolytic virus and a fourth peptide, wherein the first peptide, the second peptide, the third peptide, and the fourth peptide are each capable of inducing an immune response to at least one neoantigen, and wherein the second oncolytic virus is immunologically distinct from the first oncolytic virus. The subject may have pre-existing immunity to the at least one neoantigen. The subject may have been administered a priming composition before receiving the first boost, wherein the priming composition is capable of inducing an immune response to the at least one neoantigen.
CHILDREN'S HOSPITAL OF EASTERN ONTARIO RESEARCH INSTITUTE INC. (Canada)
Inventeur(s)
Stojdl, David
Kmiecik, Justyna
Burgess, Michael F.
Abrégé
The present disclosure relates to a sequential boost oncolytic viral immunotherapy and compositions for use in the same. More particularly, the disclosure relates to oncolytic viruses that significantly increase antigen-specific T cell-mediated immune responses when combined in a sequential heterologous boost treatment regimen.
CHILDREN'S HOSPITAL OF EASTERN ONTARIO RESEARCH INSTITUTE INC. (Canada)
UNIVERSITY OF OTTAWA (Canada)
Inventeur(s)
Persano, Stefano
Stojdl, David
Abrégé
A lipid nanoparticle composition is disclosed. The lipid nanoparticle composition includes: a core, and a lipid mixture encapsulating the core. The core includes: (i) a complex of a poly-(beta-amino ester) polymer with DNA or RNA; or (ii) a peptide. The lipid mixture encapsulating the core includes: (a) N1-[2-((1S)-1-[(3-aminopropyl)amino]-4-[di(3-amino-propyl)amino]butylcarboxamido)ethyl]-3,4-di[oleyloxy]-benzamide (MVL5); (b) 1,2-dioleoyl-sn-glycero-3-phosphoethanolamine (DOPE); and (c) a polyethylene glycol (PEG)-modified lipid. Uses and methods associated with the lipid nanoparticle composition are also disclosed.
A61K 47/44 - Huiles, graisses ou cires couvertes par plus d’un des groupes Huiles, graisses ou cires naturelles ou naturelles modifiées, p. ex. huile de ricin, huile de ricin polyéthoxylée, cire de lignite, lignite, gomme-laque, colophane, cire d’abeille ou lanoline
A61K 39/00 - Préparations médicinales contenant des antigènes ou des anticorps
A61K 47/10 - AlcoolsPhénolsLeurs sels, p. ex. glycérolPolyéthylène glycols [PEG]PoloxamèresAlkyléthers de PEG/POE
A61K 47/24 - Composés organiques, p. ex. hydrocarbures naturels ou synthétiques, polyoléfines, huile minérale, gelée de pétrole ou ozocérite contenant des atomes autres que des atomes de carbone, d'hydrogène, d'oxygène, d'halogènes, d'azote ou de soufre, p. ex. cyclométhicone ou phospholipides
A61K 9/14 - Préparations médicinales caractérisées par un aspect particulier à l'état particulaire, p. ex. poudres
CHILDREN'S HOSPITAL OF EASTERN ONTARIO RESEARCH INSTITUTE INC. (Canada)
Inventeur(s)
Stojdl, David F.
Abrégé
The present disclosure provides a Farmington virus formulated to induce an immune response in a mammal against a tumour associated antigen. The Farmington virus may express an antigenic protein that includes an epitope from the tumour associated antigen. The Farmington virus may be formulated in a composition where the virus is separate from an antigenic protein that includes an epitope from the tumour associated antigen. The present disclosure also provides a prime:boost therapy for use in inducing an immune response in a mammal. The boost includes a Farmington virus, or a composition that includes a Farmington virus.
C07K 14/025 - Papovaviridae, p. ex. virus du papillome, virus du polyome, SV40, virus BK, virus JC
C07K 14/47 - Peptides ayant plus de 20 amino-acidesGastrinesSomatostatinesMélanotropinesLeurs dérivés provenant d'animauxPeptides ayant plus de 20 amino-acidesGastrinesSomatostatinesMélanotropinesLeurs dérivés provenant d'humains provenant de vertébrés provenant de mammifères
C12N 15/12 - Gènes codant pour des protéines animales
C12N 15/37 - Papovaviridae, p. ex. virus du papillome, virus du polyome, SV 40
C12N 15/40 - Protéines de virus à ARN, p. ex. flavivirus
CHILDREN'S HOSPITAL OF EASTERN ONTARIO RESEARCH INSTITUTE INC. (Canada)
Inventeur(s)
Mccart, Judith, Andrea
Stojdl, David, Francis
Ho, Tiffany, Yun-Yee
Abrégé
The disclosure provides a recombinant oncolytic poxvirus including vaccinia virus comprising one or more inactivated immunomodulatory gene selected from NIL, K1L, K3L, A46R, and/or A52R, optionally further comprising inactivated TK and/or VGF genes. The disclosure also provides methods and for the use of these recombinant oncolytic poxvirus in oncolytic virotherapy. Also provided in the disclosure are vector constructs for generating recombinant oncolytic poxviruses including for example vaccinia viruses that have one or more inactivated immunomodulatory genes.
C07H 21/04 - Composés contenant au moins deux unités mononucléotide comportant chacune des groupes phosphate ou polyphosphate distincts liés aux radicaux saccharide des groupes nucléoside, p. ex. acides nucléiques avec le désoxyribosyle comme radical saccharide
C12N 15/39 - Poxviridae, p. ex. virus de la vaccine, virus de la variole
C12N 15/85 - Vecteurs ou systèmes d'expression spécialement adaptés aux hôtes eucaryotes pour cellules animales
CHILDREN'S HOSPITAL OF EASTERN ONTARIO RESEARCH INSTITUTE (Canada)
Inventeur(s)
Figeys, Joseph Michel Daniel
Stintzi, Alain Christophe
Mack, David R.
Zhang, Xu
Ning, Zhibin
Abrégé
A method of isotope-labelling a microbiota sample. It involves providing a first microbiota sample that was obtained from a given source; exposing the first microbiota sample to an isotope enriched medium; and culturing the exposed first microbiota sample in the isotope enriched medium to obtain an isotope-labelled microbiota sample, wherein the isotope labelled metaproteome of the isotope-labelled microbiota sample is taxon specific for taxa present in the first microbiota sample when initially obtained from the given source.
C12Q 1/02 - Procédés de mesure ou de test faisant intervenir des enzymes, des acides nucléiques ou des micro-organismesCompositions à cet effetProcédés pour préparer ces compositions faisant intervenir des micro-organismes viables
C12N 1/00 - Micro-organismes, p. ex. protozoairesCompositions les contenantProcédés de culture ou de conservation de micro-organismes, ou de compositions les contenantProcédés de préparation ou d'isolement d'une composition contenant un micro-organismeLeurs milieux de culture
C12P 21/00 - Préparation de peptides ou de protéines
G01N 33/58 - Analyse chimique de matériau biologique, p. ex. de sang ou d'urineTest par des méthodes faisant intervenir la formation de liaisons biospécifiques par ligandsTest immunologique faisant intervenir des substances marquées
13.
SMC COMBINATION THERAPY FOR THE TREATMENT OF CANCER
CHILDREN'S HOSPITAL OF EASTERN ONTARIO RESEARCH INSTITUTE INC. (Canada)
Inventeur(s)
Korneluk, Robert G.
Lacasse, Eric C.
Beug, Shawn T.
Tang, Vera A.
Abrégé
The present invention includes methods and compositions for enhancing the efficacy of SMCs in the treatment of cancer. In particular, the present invention includes methods and compositions for combination therapies that include an SMC and at least a second agent that stimulates one or more apoptotic or immune pathways. The second agent may be, e.g., an immunostimulatory or immunomodulatory compound or oncolytic virus.
CHILDREN'S HOSPITAL OF EASTERN ONTARIO RESEARCH INSTITUTE INC. (Canada)
Inventeur(s)
Korneluk, Robert G.
Beug, Shawn T.
Lacasse, Eric C.
Tang, Vera A.
Abrégé
The present inventionIncludes methods and compositions for enhancing the efficacy of SMCs in the treatment of cancer. In particular, the present invention includes methods and compositions for combination therapies that include an SMC and at least a second agent that stimulates one or more apoptotic or immune pathways. The second agent may be, e.g., an immunostimulatory or immunomodulatory compound or oncolytic virus.
CHILDREN'S HOSPITAL OF EASTERN ONTARIO RESEARCH INSTITUTE INC. (Canada)
Inventeur(s)
Stojdl, David F.
Abrégé
The present disclosure concerns an oncolytic virus for the treatment of cancer, such as in brain cancer, for example glioblastoma. The oncolytic virus may exhibit reduced levels of neurotoxicity. The oncolytic virus may be an isolated viral particle capable of producing a cDNA polynucleotide that includes a sequence according to SEQ ID NO: 1 when the virus is in a host cell. The oncolytic virus may be an isolated viral particle that includes an RNA polynucleotide that includes a sequence according to SEQ ID NO: 2. The oncolytic virus may be an isolated viral particle having a genome that includes open reading frames that encode: proteins having sequences comprising SEQ ID NOs: 3, 4, 5, 6 and 7; or variants thereof.
Disclosed are new approaches to detecting adenosine deaminase (ADA) deficiency. There is provided a method of determining ADA activity, comprising: dividing a sample obtained from blood into two portions, adding an ADA inhibitor to one portion, measuring levels of ADA activity in both portions, and determining the ADA activity. Also provided is a method of measuring ADA substrate, comprising: measuring an ADA substrate in a sample obtained from blood of subject, and comparing this to at least one control sample obtained from blood and comprising an ADA inhibitor, and a known quantity of the ADA substrate. Multiplexed methods of measuring ADA enzymatic activity along with other metabolic markers are also provided. The methods are particularly useful for the analysis of samples obtained from dried blood spots (DBSs), and may be incorporated into existing newborn screening programs. Associated diagnostic methods, control samples, and apparatuses are also disclosed.
C12N 1/34 - Procédés utilisant la culture en mousse
C12Q 1/34 - Procédés de mesure ou de test faisant intervenir des enzymes, des acides nucléiques ou des micro-organismesCompositions à cet effetProcédés pour préparer ces compositions faisant intervenir une hydrolase
G01N 33/48 - Matériau biologique, p. ex. sang, urineHémocytomètres
G01N 33/483 - Analyse physique de matériau biologique
G01N 33/49 - Analyse physique de matériau biologique de matériau biologique liquide de sang
G01N 33/58 - Analyse chimique de matériau biologique, p. ex. de sang ou d'urineTest par des méthodes faisant intervenir la formation de liaisons biospécifiques par ligandsTest immunologique faisant intervenir des substances marquées
17.
COMPOSITIONS AND METHODS FOR GLIOBLASTOMA TREATMENT
CHILDREN'S HOSPITAL OF EASTERN ONTARIO RESEARCH INSTITUTE INC. (Canada)
Inventeur(s)
Stojdl, David F.
Abrégé
The present disclosure concerns a Farmington rhabdovirus for the treatment of cancer, for example brain cancer, such as glioblastoma. The virus has a genome that includes open reading frames that encode: proteins having sequences comprising SEQ ID NOs: 3, 4, 5, 6, 7, and at least one additional protein implicated in cell death; or variants thereof. Examples of such an additional protein include: mixed lineage kinase domain-like (MLKL), casepase 2 (CASP2), p15 BH3 interacting-domain death agonist, transcript variant 2 (BIDv2), and Bcl-2- associated death promoter (BAD). Specific examples of these proteins have the sequences shown in SEQ ID NOs: 13, 15, 17 and 19, respectively.
C07K 14/145 - Rhabdoviridae, p. ex. virus de la rage, virus Duvenhage, virus Mokola ou virus de la stomatite vésiculaire
C07K 14/47 - Peptides ayant plus de 20 amino-acidesGastrinesSomatostatinesMélanotropinesLeurs dérivés provenant d'animauxPeptides ayant plus de 20 amino-acidesGastrinesSomatostatinesMélanotropinesLeurs dérivés provenant d'humains provenant de vertébrés provenant de mammifères
CHILDREN'S HOSPITAL OF EASTERN ONTARIO RESEARCH INSTITUTE INC. (Canada)
Inventeur(s)
Korneluk, Robert G.
Lacasse, Eric C.
Beug, Shawn T.
Tang, Vera A.
Abrégé
The present invention includes methods and compositions for enhancing the efficacy of SMCs in the treatment of cancer. In particular, the present invention includes methods and compositions for combination therapies that include an SMC and at least a second agent that stimulates one or more apoptotic or immune pathways. The second agent may be, e.g., an immunostimulatory compound or oncolytic virus.
CHILDREN'S HOSPITAL OF EASTERN ONTARIO RESEARCH INSTITUTE INC. (Canada)
OTTAWA HOSPITAL RESEARCH INSTITUTE (Canada)
MCMASTER UNIVERSITY (Canada)
Inventeur(s)
Stojdl, David, F.
Bell, John, Cameron
Lichty, Brian
Pol, Jonathan
Abrégé
There is described a kit for use in inducing an immune response in a mammal, the kit includes: a first virus that expresses MAGEA3, Human Papilloma Virus E6/E7 fusion protein, human Six-Transmembrane Epithelial Antigen of the Prostate protein, or Cancer Testis Antigen 1, or a variant thereof as an antigenic protein and that is formulated to generate an immunity to the protein or variant thereof in the mammal. The kit also includes a Maraba MG1 virus encoding the same antigen, or a variant of the same antigen. The Maraba MG1 virus is formulated to induce the immune response in the mammal. The first virus is immunologically distinct from the Maraba MG1 virus.
C07K 14/145 - Rhabdoviridae, p. ex. virus de la rage, virus Duvenhage, virus Mokola ou virus de la stomatite vésiculaire
C07K 14/47 - Peptides ayant plus de 20 amino-acidesGastrinesSomatostatinesMélanotropinesLeurs dérivés provenant d'animauxPeptides ayant plus de 20 amino-acidesGastrinesSomatostatinesMélanotropinesLeurs dérivés provenant d'humains provenant de vertébrés provenant de mammifères
CHILDREN'S HOSPITAL OF EASTERN ONTARIO RESEARCH INSTITUTE INC. (Canada)
OTTAWA HOSPITAL RESEARCH INSTITUTE (Canada)
Inventeur(s)
Stojdl, David
Bell, John, Cameron
Abrégé
Described herein is an isolated viral particle having a genome that includes open reading frames that encode: Maraba proteins N, P, and L, or variants thereof; as well as Maraba protein M or protein delta 51M, or variants thereof; and a Bahia Grande G protein, a LCMV G protein, or an Ebola G protein. Maraba protein N may have a sequence which includes SEQ ID NO: 1. Maraba protein P may have a sequence which includes SEQ ID NO: 2. Maraba protein L may have a sequence which includes SEQ ID NO: 3. Maraba proteins M and delta 1M may have sequence which include SEQ ID NO: 4 and 5, respectively. Bahia Grande G protein may have a sequence which includes SEQ ID NO: 6. LCMV G protein may have a sequence which includes SEQ ID NO: 7. Ebola G protein may have a sequence which includes SEQ ID NO: 8.
C12N 7/01 - Virus, p. ex. bactériophages, modifiés par l'introduction de matériel génétique étranger
A61K 35/12 - Substances provenant de mammifèresCompositions comprenant des tissus ou des cellules non spécifiésCompositions comprenant des cellules souches non embryonnairesCellules génétiquement modifiées
CHILDREN'S HOSPITAL OF EASTERN ONTARIO RESEARCH INSTITUTE INC. (Canada)
Inventeur(s)
Stojdl, David F.
Abrégé
The present disclosure concerns an oncolytic virus for the treatment of cancer, such as in brain cancer, for example glioblastoma. The oncolytic virus may exhibit reduced levels of neurotoxicity. The oncolytic virus may be an isolated viral particle capable of producing a cDNA polynucleotide that includes a sequence according to SEQ ID NO: 1 when the virus is in a host cell. The oncolytic virus may be an isolated viral particle that includes an RNA polynucleotide that includes a sequence according to SEQ ID NO: 2. The oncolytic virus may be an isolated viral particle having a genome that includes open reading frames that encode: proteins having sequences comprising SEQ ID NOs: 3, 4, 5, 6 and 7; or variants thereof.
CHILDREN'S HOSPITAL OF EASTERN ONTARIO RESEARCH INSTITUTE INC. (Canada)
Inventeur(s)
Stojdl, David, F.
Abrégé
The present disclosure concerns an oncolytic virus for the treatment of cancer, such as in brain cancer, for example glioblastoma. The oncolytic virus may exhibit reduced levels of neurotoxicity. The oncolytic virus may be an isolated viral particle capable of producing a cDNA polynucleotide that includes a sequence according to SEQ ID NO: 1 when the virus is in a host cell. The oncolytic virus may be an isolated viral particle that includes an RNA polynuclotide that includes a sequence according to SEQ ID NO: 2. The oncolytic virus may be an isolated viral particle having a genome that includes open reading frames that encode: proteins having sequences comprising SEQ ID NOs: 3, 4, 5, 6 and 7; or variants thereof.
CHILDREN'S HOSPITAL OF EASTERN ONTARIO RESEARCH INSTITUTE INC. (Canada)
Inventeur(s)
Bell, John, C.
Stojdl, David, F.
Abrégé
Embodiments of the invention include compositions and methods related to Maraba virus and their use as anti-cancer therapeutics. Such rhabdoviruses possess tumor cell killing properties in vitro and in vivo.
CHILDREN'S HOSPITAL OF EASTERN ONTARIO RESEARCH INSTITUTE INC. (Canada)
Inventeur(s)
Stojdl, David
Abrégé
Embodiments of the invention include compositions and methods related to non- VSV rhabdoviruses and their use as anti-cancer therapeutics. Such rhabdo viruses possess tumor cell killing properties in vitro and in vivo.
The invention features a method for identifying a compound that inhibits apoptosis (e.g., ER stress-induced apoptosis). This method includes the steps of (a) contacting a polypeptide having a HIAP2 BIR2 or HIAP2 BIR1-BIR2 linker region (e.g., a human HIAP2 BIR2 or HIAP2 BIR1-BIR2 linker region) with a candidate compound; and (b) determining whether the candidate compound binds the polypeptide.
G01N 33/566 - Tests immunologiquesTests faisant intervenir la formation de liaisons biospécifiquesMatériaux à cet effet utilisant un support spécifique ou des protéines réceptrices comme réactifs pour la formation de liaisons par ligand
A61K 31/7105 - Acides ribonucléiques naturels, c.-à-d. contenant uniquement des riboses liés à l'adénine, la guanine, la cytosine ou l'uracile et ayant des liaisons 3'-5' phosphodiester
A61K 31/7088 - Composés ayant au moins trois nucléosides ou nucléotides
A61K 48/00 - Préparations médicinales contenant du matériel génétique qui est introduit dans des cellules du corps vivant pour traiter des maladies génétiquesThérapie génique
A61P 1/16 - Médicaments pour le traitement des troubles du tractus alimentaire ou de l'appareil digestif des troubles de la vésicule biliaire ou du foie, p. ex. protecteurs hépatiques, cholagogues, cholélitholytiques
A61P 25/28 - Médicaments pour le traitement des troubles du système nerveux des troubles dégénératifs du système nerveux central, p. ex. agents nootropes, activateurs de la cognition, médicaments pour traiter la maladie d'Alzheimer ou d'autres formes de démence
brevets
